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ABSTRACT 
Corticosteroids are an often prescribed anti-inflammatory medication. 
They are used to treat disease processes of every system of the body. Those 
disease processes or procedures for which corticosteroids are often prescribed 
are cancer, bone marrow transplants, collagenous diseases (systemic lupus 
erythematosus), rheumatoid arthritis, leukemia, and anemia. 
However, despite the therapeutic benefits of corticosteroids, many 
adverse effects are possible. Gastrointestinal difficulties, steroid myopathy, 
hyperglycemia, osteoporosis, impaired cellular immunity, decreased 
neuropsychological functioning, and avascular necrosis are just a few of the 
possible adverse effects. 
Patients receiving corticosteroids will often be seen by physical therapists 
for either their primary or secondary diagnoses. Physical therapists are not 
often instructed in the possible adverse effects of corticosteroids that may occur. 
The purpose of this study was to create an increased awareness for health 
professionals (specifically physical therapists) concerning the possible adverse 
effects of corticosteroids and how these adverse effects may influence patient 
evaluation, treatment, and progression. A review of the literature was done. 
The adverse effects covered were avascular necrosis, osteoporosis, impaired 
ix 
cellular immunity, GI disturbances, neuropsychological difficulties, and steroid 
myopathy. For each of the selected adverse effects, the physiologic mechanism, 
clinical research, and therapeutic intervention were discussed. Finally, 
precautions or suggestions for the physical therapist relative to working with the 
patient on corticosteroids was offered. 
x 
CHAPTER I 
INTRODUCTION 
The definition of a physical therapist is someone who is " ... responsible 
for evaluating, planning, conducting, and supervising a physical therapy program 
••• 111(P1S0S) Many factors may exist that will alter the evaluation, treatment 
choices, and progression of a patient's rehabilitation. Medication is one of those 
factors. 
One powerful category of medication is corticosteroids (CS). The most 
common corticosteroids are cortisone, hydrocortisone, dexamethasone, 
methylprednisolone, prednisolone, and prednisone.2,3,4 These generic names 
may be marketed under many trade names. 
Corticosteroids are prescribed for their strong anti-inflammatory 
properties and chemotherapeutic qualities. Corticosteroids produce their effects 
on the body by Circulating in the blood, passing through the cell membrane, and 
attaching to intracellular receptors.s Corticosteroids exhibit anti-inflammatory 
qualities because they can alter the function of cells involved in the inflammatory 
process. These cells include macrophages, neutrophils, eosinophils, basophils, 
endothelial cells, fibroblasts, prostaglandins, and lymphocytes. On the other 
hand, chemotherapeutic qualities of CS are used to treat hematologic 
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malignancies and malignant lymphomas as well as malignant tumors.2 CS are 
also used to decrease cerebral edema or cord compression when cancer 
metastasizes to the CNS or spinal cord injury occurs.2 Corticosteroid (CS) 
receptors exist not only in the cells involved with the inflammatory process but 
also in most cells of the body; i.e., skeletal muscle. Skeletal muscle is 
considered a target organ for CS and steroid use often results in CS induced 
weakness, which is also known as steroid myopathy. 
Because of the therapeutic benefits of CS, many patients will receive 
them for either the primary and/or secondary diagnoses of any system of the 
body. The major areas for which CS are prescribed are respiratory diseases, 
allergies, hematologic disorders, collagenous diseases, disorders of the GI 
system, metabolic and endocrine disorders, hematological disorders, 
neuromuscular, cardiovascular, renal disorders, and cancer. 6 The most common 
disease processes for which CS are used are: 1) asthma, 2) rheumatoid 
arthritis, 3) ulcerative colitis, 4) Crohn's disease, 5) systemic lupus 
erythematosus (SLE), and 6) cancer.2,7-9 They are also used after any organ, 
tissue, or bone marrow transplant as one of the many anti rejection drugs these 
patients will have to take for the rest of their Iives.2 
Despite the therapeutic benefits of CS in these patient populations, a 
wide range of adverse effects also exist. In addition, just as CS are used to treat 
disorders/diseases of all systems of the body, the adverse effects may manifest 
in one or more systems of the body. A review of the literature has produced a 
3 
lengthy list of potential adverse effects.2•3•5•7 Hypertension, GI complications, 
avascular necrosis, osteoporosis, electrolyte imbalances, glucose intolerance, 
myopathy, impaired cellular immunity, atherosclerosis, hyperglycemia, and 
neuropsychological difficulties are the most commonly agreed upon adverse 
effects of CS. It is also important to note that not every patient receiving CS will 
develop any of these adverse effects. 
The adverse effects of CS may influence a physical therapist's approach 
to evaluation, treatment, and progression of a patient's rehabilitation program. 
That is why knowledge of the adverse effects of CS is important for physical 
therapists and other medical personnel. The adverse effects most pertinent to 
physical therapy are osteoporosis, gastrointestinal complications, avascular 
necrosis, reduced cellular immunity, myopathy, and neuropsychological 
difficulties. 
Thus, the purpose of this study is to create an increased awareness for 
health professionals (specifically physical therapists) concerning the possible 
adverse effects of CS and how these adverse effects may influence patient 
evaluation, treatment, and progression. The adverse effects mentioned in the 
above paragraph are discussed. The physiologic mechanism, clinical research, 
and therapeutic intervention are presented for each effect as well as precautions 
or suggestions for the physical therapist relative to working with patients 
receiving CS. 
CHAPTER II 
OSTEOPOROSIS 
Osteoporosis is probably one of the most recognized adverse effects of 
long-term corticosteroid (CS) use. A study by Grecu, Weinshelbaum, and 
Simmons 10 concluded that most bone density is lost within one year after 
initiating CS therapy. Within that first year bone density may decrease by 4-
10%. After the first year, bone loss most likely still occurs but at a much lesser 
extent. 
Mechanism 
One mechanism by which CS may induce osteoporosis is fairly well 
described in today's Iiterature.2 Another possible mechanism is briefly 
mentioned.s.11 The mechanism well described in literature begins with 
corticosteroids inducing hypocalcemia. Because the body becomes 
hypocalcemic, it will leach calcium from the skeletal system to meet its 
requirements, leading to a reduction in bone density and eventually leading to 
osteoporosis. "Steroids cause bone loss by decreasing intestinal calcium 
absorption and by increasing urinary calcium excretion by the kidney. 
Decreased blood calcium results in mild hyperparathyroidism, which in turn 
accelerates bone resorption."s(P1206) Basically there is an imbalance between 
4 
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bone destruction and bone formation. The other possible physiologic 
mechanism that may lead to osteoporosis is a reduced level of sex hormones 
which may increase bone resorption.s,11 CS decrease the level of sex hormones 
in the body by altering gonadal function and the amount of sex hormones 
produced by the ovaries and testes. 11 
Clinical Research 
Most authors agree that osteoporosis is an adverse effect of CS therapy. 
The limitation of some studies is that it is difficult to separate the effects of age 
related osteoporosis versus the effects of corticosteroids; age and 
corticosteroids most likely have an additive effect relative to osteoporosis. 
When bone density decreases, it puts the patient at a higher risk for 
fractures. Bone density in trabecular bone (such as that of the vertebrae) seems 
to be affected by CS more than is cortical bone. Boumpas et als compared 
trabecular and cortical bone densities in those receiving long-term CS versus 
those receiving intermittent CS therapy. Neither therapeutic intervention had a 
significant effect on cortical bone densities and only long-term CS therapy had a 
negative effect on trabecular bone. 
A study by Troiano, Jatkowitz, Cook, Basil, and Zito 12 found that the 
incidence of fractures was higher while the patient was receiving CS as 
compared to the incidence for an equal time period before initiation of CS 
therapy. The medical records of 103 patients with Multiple Sclerosis receiving 
CS were reviewed. The study reviewed variables such as length of treatment, 
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cumulative dose of CS, rate of fractures, and the location of fractures. The rate 
of fractures were as follows: "Overall, 26 (25%) of the patients had had a total of 
30 fractures. Twenty (19%) of the patients had 23 fractures after starting steroid 
therapy and six (6%) of the patients had seven fractures in an equivalent period 
of time preceding the initiation of steroid therapy.,,12(P1389) Most fractures were 
associated with falls, but some were precipitated by less traumatic events, such 
as turning in bed; in one case a spontaneous fracture was reported. 
Although many patients may have no option except to remain on 
corticosteroids, other medications have been used prophylactically to ward off 
osteoporosis and the increased risk of fractures. 
Therapeutic Intervention 
ProphylactiC medications which have been used with moderate results 
are 11-13 calcitrol, calcitonin, and biphosphates. The use of intermittent cyclic 
therapy (ICT) etidronate is fairly new. A study by Adachi et al11 compared the 
bone mineral density (BMD) in the lumbar spine of 68 patients being treated with 
corticosteroids. Thirty-five of those patients were treated prophylactically with 
ICT etidronate and the control group of 33 received no prophylactic treatment. 
Bone mineral density was again tested in one year. In the ICT etidronate group, 
the BMD had increased by 3.82% as compared to a 1.78% decrease in the 
control group. 
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Precautions for the Physical Therapist 
Because CS are used in many patient populations, physical therapists 
need to be aware that patients receiving long-term CS may be osteoporotic and 
special attention must be given while assessing the patient and designing a 
treatment program. For example, when manual muscle testing (MMT), the 
shortest lever arm possible should be used to reduce the amount of torque on 
the skeletal system (especially the long bones of the humerus and femur). 
Options for strengthening include using pool therapy and closed chain exercises 
to reduce the shearing forces on the bones.2 If the patient is unsteady, the use 
of an assistive device to help prevent falls is indicated. One of the most 
important things to do for the patients is to educate them in proper body 
mechanics during activities of daily living (ADLs). 
CHAPTER III 
COMPROMISED IMMUNITY 
For those receiving CS, a compromised immune system is another 
adverse effect. Corticosteroids weaken the immune system by decreasing the 
local inflammatory response which may cause the infection to spread.14 Many of 
the disease processes that require treatment with corticosteroids may have 
already put the body and the immune system in a weakened state. The 
combination of the disease process at hand and the steroid-induced 
immunosuppression can be a fatal combination. 
Mechanism 
The mechanism by which CS suppress the immune system is fairly well 
understood but also complex. One explanation begins with the depression of 
lymphocytes and monocytes 15 which occurs four to six hours following the 
administration of CS. Boumpas et al5 summarize what occurs at the cellular 
level: "glucocorticoids inhibit the access of leukocytes in inflammatory sites; 
interfere with the functions of leukocytes, endothelial cells, and fibroblasts; and 
suppress the production and effects of humoral factors involved in the 
inflammatory response."(P1198) In a sense, corticosteroids bind well to sites of 
inflammation and do not allow the leukocytes, fibroblasts, etc. to invade the site 
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and fight off the infection. Several studies exist that conclude that CS put the 
patient at a higher risk for acquiring infections.2•5•15 
Clinical Research 
A meta analysis of 71 trials involving 2000 CS treated patients concluded 
that the relative risk for infection was approximately two times that of controls.5 
Dowell and Bresee15 came to a similar conclusion. In their 1993 study, they 
concluded that the use of CS multiplies the risk (incidence) of severe varicella or 
"chicken pox." They studied 35 children who were suffering from severe 
varicella and 10,000 control subjects. The purpose of their study was to 
determine if there is a correlation between CS use and severe varicella. Sixteen 
of the 35 children in the experimental group had been exposed to some form of 
CS, whereas in the control group, only 20 out of the 10,000 subjects had been 
exposed to CS. The dosages of corticosteroids in the experimental group 
ranged from .5-2.5 mg\kg\d. Among the experimental group, four of the 16 
exposed to CS succumbed to the severe varicella. Dowell and Bresee 15 
concluded ''the odds of steroid use in otherwise immunocompetent children who 
contracted severe varicella was 178 times higher than in the general 
population. n(p225) 
Dowell and Bresee15 identified three limitations in their study. One 
limitation was the small number of subjects. Secondly, they may have 
overestimated the odds ratio. Finally, a third factor may exist that ties together 
the risk of severe varicella and the use of steroids. Regardless of the limitations 
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of the study, the authors still feel that steroid immunosuppression should be a 
concern among doctors and those receiving CS. 
Therapeutic Intervention 
In the review of the literature, no information was found on any substance 
that could be used to decrease the likliehood of steroid induced 
immunosuppression. 
Precautions for the Physical Therapist 
Physical therapists will often treat patients who are immunosuppressed by 
CS. There are many ways to protect the patient. The single most effective way 
to prevent the spread of infections is proper hand-washing techniques for the 
physical therapist and the patient.2 Jennifer Grant2 of John Hopkins Hospital 
states, "it is encouraged that patients with a white blood cell (WBC) count of less 
than 1000 mm3 or a neutrophil count of less than 5000 mm3 should wear a 
protective mask.,,(p58) Physical therapists should be responsible for using 
universal precautions and gowning and gloving when appropriate. The patient 
should be educated to avoid public areas where many people congregate as the 
possibilities of contracting an unwanted infection abound. 
CHAPTER IV 
GI COMPLICATIONS 
Gastrointestinal complications often occur in those taking CS. The most 
common complications are perforation of peptic ulcers and perforation of colonic 
diverticula. 
Mechanism 
For perforation of both peptic ulcer and colonic diverticula, there are 
separate possible mechanisms of injury. Three primary explanations of how CS 
may cause peptic ulcer perforation exist. Alexander, Schuman, and Vetto's 16 
stated mechanism of peptic ulcer perforation is by "lymphoid depletion in the 
colonic lymphoid patches, resulting in bacterial invasion and subsequent 
perforation." As discussed previously, CS leave the patient in an 
immunosuppressed condition, which decreases the leukocyte counts and leave 
the patient less able to fight off the bacteria that enter the GI tract. Finally, 
corticosteroids are also thought to decrease the turnover of the mucosal cells 
lining the GI tract leaving the lining of the GI tract susceptible to infection and 
subsequent perforation. 
A second complication is perforation of colonic diverticula. Arsura 17 
believes areas of the colon are repetitively traumatized by fecal material. If 
11 
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mucosal regeneration is slowed by CS, bacteria have a chance to invade the 
lining of the colon and eventually cause perforation.17-18 Because of CS induced 
immunosuppression, the patient is in a more vulnerable state for bacterial 
invasion.17•18 
Clinical Research 
There are many studies identifying a statistically significant correlation 
between CS use and perforation of ulcers and colonic diverticula of the GI tract. 
One study used 71 controlled trials. Subjects were randomly assigned to Group 
1 or 2. Group 1 received CS, Group 2 received non-steroidal treatment. 
Subjects were treated for four days. The incidence of peptic ulcers was 1.8% in 
Group 1 and 0.8% in Group 2.4 
Warshaw, Welch, and Ottinger18 strongly suggested that CS may cause 
perforation of the colon. Their quasi experimental study included 13 subjects 
whose average duration on steroids was 3.4 years. All subjects were receiving 
CS for diseases other than that of the bowel. Surgery to repair a perforated 
colon was needed in 10 of the 13 cases. In five cases, the areas of perforation 
were close to areas of diverticula, but in the other eight cases, the perforations 
were in unusual areas. Of the eight cases that were unusual, five had punched 
out perforations, which are not normally seen. One subject had perforations at 
the rectosigmoid colon. Other unusual findings were perforations of the 
transverse and descending colon and areas of gangrene. The authors felt that 
because of the uniqueness of the perforations and the fact that the patients were 
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being treated for diseases other than that of the GI tract, the CS therapy most 
likely contributed to the perforation in these patients. 
Dayton, Kleckner, Dennistoun, and 8rown's3 study evaluated (1) the 
incidence of steroid-related ulcer perforation and (2) the clinical problems and 
prognosis of patients with this complication. They did retrospective chart 
reviews of 151 patients with peptic ulcer perforation. Twenty-five (17%) of the 
subjects had received CS within one week of perforation. The authors agree 
that this incidence is similar to the findings of other studies and is slightly higher 
than the 5% to 10% incidence of peptic ulcer perforation found in the general 
population. Therefore, if the patient is receiving CS, he/she has a greater 
chance of peptic ulcer perforation than if he/she was not taking CS. The 
prognosis for patients was poor. There was an 85% mortality rate for those over 
50 years of age and 17% for those under 50 years of age. The authors 
concluded that CS therapy causes a significant number of all perforations and 
there is a high mortality for these patients. 
Diethelm 14 also concluded that "steroid ulceration" is a complication that 
may occur in 10% to 30% of those on CS for more than one month. He also 
reported that the dosage levels of cortisone and prednisone may be associated 
with an increased incidence of ulceration. Daily dosage levels greater than 50 
mg/d of cortisone and 20 mg/d of prednisone appear to be associated with an 
increased risk of ulceration. 
14 
Carson et al19 disagreed with these conclusions. The authors found the 
overall risk of GI complications in users of CS to be 2.8 per 10,000 person-
months. They concluded that the rate of GI complications did not warrant the 
use of prophylactic medication. 
Therapeutic Intervention 
Perforation of the GI tract often ends in surgical intervention. Prior to 
perforation, however, prophylactic medications may ward off steroid-induced 
complications. 
Antacids and H2 blockers have been used with moderate success to 
guard against ulcer formation 14 and the use of ranitidine has also been 
suggested.20 Seale and Compton4 disagree with the prophylactic use of 
medications, such as antacids and H2 blockers, as their use is not warranted.4 
Precautions for the Physical Therapist 
As physical therapists, recognizing the signs and symptoms of ulceration 
and/or perforation would facilitate immediate referral to a physician. Signs and 
symptoms may include 1) pain which is burning, gnawing, or aching, 
2) soreness, 3) an empty feeling, or 4) hunger.21 Pain is usually unrelenting and 
may range from mild to severe. Pain may be lessened by the use of dairy 
products, antacids, or H2 blockers. 
CHAPTER V 
AVASCULAR NECROSIS 
Avascular necrosis (AVN) is a recognized adverse effect of CS 
therapy.22-26 Four common features of corticosteroid-induced AVN exist.27 First, 
no known trauma is implicated. Second, no other underlying cause of 
nontraumatic avascular necrosis is found. Third, the patient has been receiving 
corticosteroids for an extended period of time and in excess of physiological 
requirements. Last of all, the disease process for which the patient is receiving 
CS does not cause AVN. 
AVN most commonly occurs in the hip joint.24 The knee, ankle, shoulder, 
elbow, and wrist have also been implicated.14 When avascular necrosis affects 
the femoral head, total hip arthroplasty is the most common surgical intervention. 
The specific cause of steroid-induced avascular necrosis is not known, but a few 
causes have been hypothesized. 
Mechanism 
Wang, Sweet, Reger, and Thompson28 proposed three possible 
mechanisms of steroid-induced AVN. The first theory is that the blood hyper-
coagulates and there is subsequent vascular insufficiency to the femoral head. 
The second possible cause of AVN is osteoporosis which may eventually lead to 
15 
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fracture and collapse of the femoral head. The last mechanism of AVN may be a 
result of hyperlipidemia. The alteration of fat metabolism by CS may cause the 
liver to become excessively fatty and cause the liver to release small fat emboli. 
These small fat emboli may impair the circulation of the femoral head, causing 
bone death and resultant AVN. This latter theory appears to be the most 
popular school of thought.3.22.24.25.27.28 
A study by Fisher et al22 supports this theory. Fisher studied 66 New 
Zealand rabbits. The 66 rabbits were split into two experimental groups and one 
control group. Two experimental groups of 30 subjects each were formed. The 
only difference between the groups was that they received slightly different 
corticosteroids. The six remaining rabbits made up the control group. The 
rabbits in the experimental group received dosages of CS in excess of 
physiological requirements. Five rabbits in each experimental groups and one 
from the control group were killed each month for six months. Histological and 
general autopsies were done. The results indicated that high doses of CS cause 
hyperlipidemia and an excessively fatty liver. The reason for hyperlipidemia is 
not well understood. One theory states that CS cause lipid mobilization in the 
adipose tissue. The increased lipid mobilization causes the liver to become so 
full of fat that the cells eventually burst. Fat emboli enter the bloodstream via 
the hepatic circulation. Through the hepatic circulation, the emboli enter the 
circulatory system of the heart and lungs and are transported to the periphery of 
17 
the circulatory system. Fisher and associates found fat emboli in subchondral 
bone of the rabbits and areas of osteocytic death after three to five months. 
Clinical Research 
Alarcon and associates26 describe an atypical case of a 48-year-old 
woman who developed AVN of the femoral head after long-term corticosteroid 
use. She was receiving corticosteroids for "feigned" bronchial asthma. 
"Feigned" bronchial asthma is considered a factitious disorder. "Factitious 
disorders are characterized by physical and/or psychological symptoms that are 
intentionally produced or feigned.,,26(P139) In 1990, the woman was evaluated for 
refractory asthma. She stated she had had asthma since she was 13 years old 
but her asthma did not become severe enough to elicit the use of CS until she 
was 37 years old. She used parenteral, oral and inhaled corticosteroids. Her 
history and physical revealed that she had undergone 11 knee surgeries, two of 
which were total knee arthroplasties. At the time of the evaluation, she relied on 
a wheelchair for locomotion secondary to the condition of her knees. She had a 
host of other problems and was receiving nine different medications. At the time 
of her evaluation, chest X-rays were unremarkable as were the results of her 
pulmonary function tests. In 1990 and again in June 1991, she was advised to 
decrease the use of her CS. She was lost to follow up until March 1992 when 
she presented with left hip pain. The diagnosis of AVN was made. 
Conservative treatment with core decompression was done, but in June 1992, 
she required a total hip arthroplasty (THA). During this hospitalization time, she 
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did agree to taper her CS dosage. At discharge she was taking only 8 mg of 
prednisone every other day and eventually was able to taper it to 5 mg every 
other day. Alarcon and associates stated that no cause of AVN, other than CS 
could be shown. 
Not only is AVN implicated in long-term corticosteroid use, such as in the 
above case, but is also infrequently noted in short-term CS use. Anderton, Orth, 
and Helm25 reported the case study of a 27-year-old male whom after a seven-
day course of dexamethasone for increased intercranial pressure presented with 
avascular necrosis of both humeral heads and femoral heads. The man was first 
seen for complaints of shoulder pain that had persisted for one year. No history 
of trauma to the shoulders was present. Two years prior to the onset of 
symptoms the patient had been treated with oral dexamethasone for increased 
intercranial pressure. No definitive diagnosis was given for the increased 
intercranial pressure. He received 4 mg of dexamethasone every six hours for 
seven days. Complete recovery was achieved. At the time of evaluation, three 
years after receiving the dexamethasone, range of motion (ROM) in both 
shoulders was compromised. X-rays showed marked AVN of bilateral shoulders 
and moderate involvement at both hips. Other possible causes of AVN from 
disease processes or systemic involvement were ruled out. Anderton et al 
concluded that even a short duration of CS does not rule out the possibility of 
AVN. 
19 
Fisher and Bickel27 along with help of Patterson and company reviewed 
77 cases of non-traumatic avascular necrosis at the Mayo Clinic. Patient 
histories were reviewed and prescriptions for CS were noted. Prednisone was 
the most common drug prescribed. Every case except one was receiving 
dosages in physiological excess. Of the 77 subjects, 23 were receiving CS for 
collagen-vascular difficulties, 16 for dermatological problems, 5 for hematologic 
problems, 7 for gout, 5 for pulmonary disease, and 21 for miscellaneous 
diseases. The time period between the onset of symptoms and diagnosis of 
AVN, via X-rays, was determined. The average time between initiation of CS 
treatment and onset of symptoms was nine months. All cases had the classic 
signs of corticosteroid-induced AVN. 
Therapeutic Intervention 
In the review of the literature, no reference was made to any prophylactic 
medications that offset the chance of AVN in patients receiving corticosteroids. 
Intervention normally occurs only after the diagnosis of AVN has been made. By 
the time AVN is diagnosed, it has usually progressed so far that surgical 
intervention is needed.2,18,26,27 With avascular necrosis of the femoral head, total 
hip arthroplasty (THA) is the intervention of choice.14 Total hip arthroplasty 
allows the patient to be free of pain and improve his/her ambulatory skills. 
A fairly new conservative treatment of AVN of the femoral head is showing 
promise as an option to THAs. The new procedure involves using a 
vascularized fibular graft.23 Malizos and associates salvaged 10 hips of eight 
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patients using a vascularized fibular graft. All patients experienced relief of pain 
following surgery. Patients utilized a pair of crutches for six months and 
advanced to one crutch for three more months. Not one of the patients needed 
any additional hip surgeries in the two-year follow-up of this study. 
Precautions for the Physical Therapist 
Once a patient is diagnosed with AVN, little to nothing can be done to 
prevent the progression of AVN. A conservative way to alleviate pain is the use 
of a cane. Another way to alleviate pain and prevent further collapse of the bone 
is to exercise the surrounding joint musculature in a non-weight bearing 
position.2 However, this conservative treatment will most likely not provide 
enough relief for the patient and surgical intervention will be needed. 
As a physical therapist, knowing the signs and symptoms of AVN will 
allow for differential diagnosis and referral to a physician.29 Pain is the major 
patient complaint. The pain is localized to the joint and the patient will usually 
complain of stiffness. Upon palpation, the patient may complain of tenderness 
and the joint may be swollen. Restricted range of motion will be noted. 
CHAPTER VI 
NEUROPSYCHOLOGICAL DIFFICULTIES 
Many neuropsychological symptoms have presented in patients receiving 
corticosteroids. The most common neuropsychological side effects of CS in 
adults are euphoria, depression, and psychotic reactions characterized by 
delusion, hallucination, stupor, and catatonia.30 The most common 
neuropsychological side effects in children are affective changes, insomnia, 
restlessness, depression, reduced verbal memory, increased irritability, and 
fatigue.31 The effects of CS on neuropsychological functioning are variable. In 
the systemic lupus erythematosus (SLE) patient population, CS have been found 
to improve cognition, mood, and symptom rating.32 The intensity of 
psychological changes may depend on dosage, sensitivity of the patient, and the 
patient's underlying personality.2 
Mechanism 
In the review of the literature, no explanation for the alteration in an 
adult's neuropsychological functioning was offered. For children, one 
hypothesis has been stated.33 Corticosteroids suppress the formation of 
adrenocorticotropic hormone (ACTH), a naturally occurring hormone in the body. 
Naturally occurring glucocorticosteroids are said to facilitate brain maturation. 
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With the use of oral, parenteral, or inhaled corticosteroids, ACTH production is 
suppressed, therefore possibly delaying full formation of the central nervous 
system.33 
Clinical Research 
The first case study relative to neuropsychological functioning is that of a 
17-year-old adult male who received many different CS for a bout of ulcerative 
colitis and who eventually developed steroid induced stupor (depression).34 He 
was given hydrocortisone (HC) for two days at 100 mg q.Ld. While on the HC, 
he experienced an anxiety attack. He was next given oral prednisone for six 
days at 20 mg t.Ld. His ulcerative colitis symptoms exacerbated and he was 
again put on HC at 100 mg q.Ld. This time while on HC, he became extremely 
agitated and made a suicide attempt. The ulcerative colitis improved and his 
medication was switched to ACTH at 40 units Lm. daily. This dosage was 
decreased gradually over 10 days. After these 10 days, his bowel problems 
were markedly improved but his psychological state had deteriorated and he 
went into a catatonic stupor. 
He was given neuroleptic medication, and over the next four weeks, his 
stupor mildly improved while his psychomotor functioning only moderately 
improved. He again became suicidal. Because of the ineffectiveness of the 
neuroleptic medications, electroconvulsive therapy (ECT) was used. He 
responded very well to a course of ECT comprised of five treatments. The 
intensity of the symptoms in this patient was most likely precipitated by the high 
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dose of CS that he was receiving and the fact that he was receiving them 
intravenously. Medications injected intravenously are rapidly absorbed in the 
bloodstream and remain more concentrated. His personal sensitivity to the CS 
may also have been a factor. It was noted that family and personal history of 
psychological problems was unremarkable. 
Neuropsychological changes occur not only in adults but also in children. 
Bender, Lerner, and Poland31 studied the psychological functioning of 32 
children, ages 8-16 years old (mean=14 years), who were currently hospitalized 
for exacerbations of severe asthma. The children received burst therapy of oral 
prednisone, a common CS, as well as inhaled CS and oral theophylline. Burst 
CS therapy uses alternating high/low dosage days, with high dosages averaging 
61.4 mg and low dosages averaging 6.97 mg. All subjects were evaluated at 
high steroid and low steroid dose. 
Psychological functions that were tested included hyperactivity, fine motor 
control, mood, attention, impulsivity, and memory. Other areas assessed were 
asthma severity, intelligence, socioeconomic status, and family functioning. All 
testing was done while the child's asthma symptoms were stable. Three areas 
of psychological functioning were found to significantly fluctuate between high 
and low steroid dosage days, while the other areas were relatively unchanged. 
All children reported higher anxiety levels during high versus low dose days. 
Verbal memory scores were decreased and the children also scored higher on 
the test for depression. Bender and associates31 found no factors that would 
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indicate the above changes were from anything other than the steroids. In 
addition, age, intelligence, socioeconomic status, and asthma severity did not 
predict a child's susceptibility to neuropsychological difficulties. However, 
impaired psychosocial functioning and family dysfunction were moderately 
associated with mood and memory deterioration. This study showed how 
dosage, patient susceptibility, and underlying personality may affect sensitivity to 
CS. 
Most studies dealing with neuropsychological functioning in patients 
receiving corticosteroids report a decrease in CNS functioning.3o,31,33,34 However, 
Denburg, Denburg, and Carbotte32 reported improvement in cognition, mood, 
and/or systemic lupus erythematosus (SLE) symptom rating in ten women after 
low doses of CS. The 10 women participating in the study had not received CS 
for at least six months prior to this study. They completed three randomly 
assigned drug/placebo pairings. Those receiving CS had 0.5 mg/kg of 
prednisone daily. Analysis of variance (AN OVA) yielded "positive drug effects 
for cognition, mood, and SLE symptom ratings.,,32(P1311) Despite the short time 
this study was run, the authors feel that more research should be carried out in 
this area because of positive CS effects on the patient living with SLE. 
Therapeutic Intervention 
In the review of the literature, one prophylactic medication was noted.3D 
Lithium has been used prophylactically to decrease the neuropsychological side 
25 
effects of CS in people with multiple sclerosis and retrobulbar neuritis. Mild to 
moderate results have been achieved. 
Precautions for the Physical Therapist 
As physical therapists, you cannot alter the moods of your patient. But 
being sensitive to changes in your patient's personality or mood is very 
important if he/she is receiving CS. If intense personality and mood changes are 
observed, the physician should be notified so possible adjustments in dose and 
form of CS may be made. 
CHAPTER VII 
STEROID MYOPATHY 
Steroid myopathy is a common adverse effect of corticosteroids. In the 
literature, there are two forms of steroid myopathy.2.3.7.8.35-39 The two forms are 
chronic steroid myopathy and acute necrotizing myopathy. 
Chronic steroid myopathy presents with distinguishing 
characteristics.2.7.8.35.38 The onset of muscle weakness is insidious, chronic, and 
painless. Weakness is symmetrical and begins in the pelvic girdle, moving to 
the shoulder girdle and then to the distal extremities. Type liB (fast twitch) 
muscle fibers are the most often affected. Tests will reveal an elevated creatine 
excretion in the urine which is an indicator of protein wasting of the muscles. 
Although pain is not the main complaint, patients may complain of mild myalgia 
and arthralgia. 
Acute necrotizing steroid myopathy is associated with the use of 
corticosteroids and neuromuscular blockades (NMBs). It most often occurs 
when NMBs are used to paralyze the respiratory muscles of patients who are 
suffering from status asthmaticus. NMBs allow easy intubation by paralyzing the 
respiratory muscles that are in spasm. Intubation is necessary so the patient 
can receive the proper ventilation he/she needs, by way of a respirator or 
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mechanical ventilation. The severe nature of status asthmaticus often requires 
that patients be maintained on both CS and NMBs for an extended period of 
time. Acute necrotizing steroid myopathy is discovered when the use of NMBs 
are discontinued. Acute nectrotizing steroid myopathy has also been associated 
with the use of steroids alone. 
Both etiologies of acute steroid myopathy are characterized by the 
following signs and symptoms.35,37,39 They both have an acute onset. Moderate 
to severe flaccid weakness will develop and atrophy of the muscles will be 
evident. In acute steroid myopathy, the distal extremities are the most severely 
affected. High creatine excretion will also be noted. Electromyographic (EMG) 
readings will give mixed results. 
Both chronic and acute steroid myopathy are reversible with exercise and 
dose reduction of both NMBs and CS.2 Complete recovery may take from one to 
four months or up to two years.2 
Mechanism 
The mechanisms leading to chronic or acute steroid myopathy can only 
be hypothesized2,7,35,36,38,40 One theory is that corticosteroids cause an 
accelerated breakdown of muscle protein.35 Skeletal muscle has many CS 
receptors and is considered a "target" organ of CS.2 The breakdown of muscle 
protein may be induced by corticosteroids by "decreased uptake of amino acids 
by skeletal muscle and inhibition of amino acid incorporation into proteins.,,2(p59) 
It has also been theorized that when muscle is immobilized, either naturally or 
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induced by NMBs, the number of corticosteroid receptors increase.35,36,40 The 
increased number of receptors causes the patient to become hypersensitive to 
the deleterious effects of CS and accelerate muscle wasting. 
The catabolic effects of CS are most pronounced in the muscles that are 
the least active in protein synthesis.2 When muscle is exercised on a regular 
basis, it becomes more active in protein synthesis than when it is immobilized or 
not exercised on a regular basis. This also supports the theory that immobilized 
muscle will be more susceptible to myopathy. Therefore, if a person is on CS 
and does not exercise regularly, he/she may be more at risk for steroid 
myopathy. Because their muscles are not active in protein synthesis and 
because they may contain more CS receptors, people who do not exercise 
regularly are most affected by the catabolic effects of CS. Horber, Scheidegger, 
GrOnig, and Frey40 concluded that exercise may reduce the effects of steroid 
myopathy. Their study will be discussed in further detail later in this chapter. 
Clinical Research 
Askari, Vignos, and Moskowitz8 presented a case study of eight women 
who developed chronic steroid myopathy while receiving high doses of 
prednisone. They were receiving prednisone for various disease processes of 
connective tissue: 1) polymyositis, 2) systemic lupus erythematosus (SLE), 
3) rheumatoid arthritis (RA), and 4) shoulder hand syndrome (SHS). All of the 
women experienced an insidious onset of weakness. In almost all of the women 
muscle weakness was symmetrical and most pronounced in the pelvic girdle with 
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less involvement at the shoulder girdle and distal musculature. Five of the 
women reported diffuse myalgia. Creatine excretion was elevated in all the 
women. The authors concluded that no correlation existed between the extent of 
the myopathy and the cumulative dose of CS that the patient had received. All 
the women recovered from this bout of steroid myopathy through dose reduction 
of CS and an active exercise program. None of the women showed a relapse of 
myopathy during the follow-up time of 120 to 360 days. As a point of interest, all 
of the women had developed at least two or more of the other adverse effects of 
CS, with osteoporosis being the most common. 
Jennifer Grant2 adapted a functional classification system from this case 
study (Table 1 ).38 This classification uses difficulty in functional activities to 
determine the level of weakness. During Class I, or advanced level of 
functioning, the patient only has difficulty in climbing stairs. In Class 2, or high 
level of functioning, the patient cannot rise from a chair without assistance of 
some kind. If patients cannot walk without assistance, they are classified as 
Class 3, or intermediate level of functioning. In the final class, Class 4, or low 
level of functioning, patients cannot elevate their eXtremities or move in bed. 
Pangyres, Squier, Mills, and Newsom-Davis38 reported the case study of a 
13-year-old Greek girl who developed acute steroid myopathy from steroids 
alone. NMBs were not used in this case. The child was receiving CS for 
myasthenia gravis. She had received a total dose of 5.48 grams of 
methylprednisolone. Weakness was most evident distally. She was unable to 
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Table 1.-Functional Classification of Muscle Weaknessa 
Class Level Functional Capacity 
1 Advanced Has difficulty in climbing stairs 
2 High Cannot rise from chair 
3 Intermediate Cannot walk without assistance 
4 Low Cannot elevate extremities or move in bed 
aFunctional classification categories are adapted from Askari A, Vingnos PJ, 
Moskowitz RW. Steroid myopathy in connective tissue disease. Am J Med. 
1976;61 :485-492 and Grant J. Corticosteroid side effects: implications for PT. 
PT Mag Phys Ther. 1994;2:56-60. 
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lift her legs from the bed. Her facial muscles were also affected and she had 
difficulty swallowing and talking. Tendon reflexes were absent with the 
exception of bilateral tricep jerks. EMG studies showed normal motor and 
sensory conduction. The clinical features of this case did not appear to be from 
the myasthenia gravis. Signs and symptoms of myasthenia gravis are21 ptosis, 
diplopia, and muscle fatigability. Ocular muscles are affected in 85% of the 
cases. Deep tendon reflexes are normal. Because the signs and symptoms did 
not fully correlate with myasthenia gravis, the authors felt that a large dose of CS 
was the possible cause of the weakness. Myasthenia gravis at times blocks 
transmission at the neuromuscular junction such as a neuromuscular blockade 
works to immobilize the muscles. Therefore, the muscles are less active in 
protein synthesis and become hypersensitive to the myopathic effects of CS, as 
stated previously in this chapter.38 
A third form of steroid myopathy is that induced by a combination of CS 
and NMBs. Steroids and NMBs may be used together when a patient goes into 
status asthmaticus as described earlier.9,35,36,39,41 
A case study by Griffin and colleagues41 was carried out on a 29-year-old 
man. He came to the emergency room with wheezes and signs of an upper 
respiratory tract infection (URI). His past medical history was positive for steroid 
dependent asthma. Because of his abnormal arterial blood gas (ABG) readings, 
he was intubated immediately. Before intubation, NMBs were used to facilitate 
the process. He remained on CS and NMBs for many days to aid with 
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ventilation and proper air exchange. On day 16 of his hospitalization, all NMBs 
and sedatives were discontinued but he remained on a ventilator. On 
examination, after discontinuation of NMBs, flaccid quadriplegia existed. Deep 
tendon reflexes were severely decreased but sensation was intact. Myoglobin 
was detected in the urine, indicating muscle breakdown. He was weaned from 
the respirator on day 31, and with the help of physical therapy, he was able to 
ambulate independently after one month. The authors felt that this patient's 
flaccid quadriplegia was due to the combination of steroids and NMBs as the 
patient had full nutritional support all through his hospitalization, his electrolytes 
were kept in balance, and he had no past medical history of a neuromuscular 
disorder. 
Hirano et al35 presented a similar case study. An 18-year-old male was 
admitted to the hospital because of a severe asthma attack. He was treated with 
intravenous (IV) methylprednisone and paralyzed with vecuronium (a NMB) 
before intubation and for the next 12 days. Following discontinuation of NMBs, 
he had flaccid quadriplegia and had lost 10 kg of body weight. He remained on 
the methylprednisone. He was mentally alert and cranial nerves were intact. 
Sensation was normal and deep tendon reflexes were present. Nerve 
conduction studies were unremarkable. On day 42 he was extubated, his 
methylprednisone was decreased and he began to improve. On day 68 he was 
able to walk short distances in the parallel bars. Because of the lack of 
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neurogenic changes, the authors believed that the flaccid quadriplegia was due 
to a combination of CS and NMBs. 
Therapeutic Intervention 
Three options exist to lessen the effects of steroid myopathy. The first 
option is either discontinuing the CS or decreasing the dosage.7•8 The second 
option is changing the medication to another steroid derivative.8 The last option 
is to institute an active exercise program for those who receive corticosteroids. 
Horber, Scheidegger, GrOnig, and Frey40 concluded that myopathy can be 
reversed by active exercise. "The purpose of their research was 1) to quantify 
the decreases in thigh muscle strength in patients with prednisone and 2) to 
establish whether the thigh muscle area can be increased and its function 
improved by training."(p83) The study included 24 subjects (12 experimental and 
12 control subjects). The 12 in the experimental group were all at least six 
months status post renal transplantation and were receiving 12.6 ± 3.3 mg/day of 
prednisone. The 12 control subjects were not currently partiCipating in any 
physical training or receiving CS. A Cybex II was used to assess muscle 
strength and power. Isokinetic tests were done on five occasions; specifically, on 
two different days before training, on day 35 of training, and on two days post 
training. The 12 experimental subjects trained isokinetically on the Cybex II 
three times per week for 50 days. To determine thigh muscle area and density, 
computerized tomography (CT) of the thigh was done. As compared to the 
control group, before instituting training, the experimental group had 1) a higher 
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fat to muscle ratio, 2) a lower mean torque, and 3) a decreased total work output. 
At the end of training, the two groups were equal in the three tested areas. This 
suggests that active exercise may offset the adverse effects of prednisone. 
Precautions for the Physical Therapist 
It is important for the physical therapist to differentiate between chronic 
and acute steroid myopathy. The signs and symptoms of each of the 
myopathies were presented in the introduction to this chapter. One red flag for 
the physical therapist is to note any increase in creatine excretion (above the 
normal) in the urine, which indicates protein catabolism. This seems to be an 
accurate indicator of even mild myopathy.2 
With an active exercise program the patient will improve. However, return 
of strength may be fast or slow. Complete recovery may be as quick as one to 
four months or it may take up to one or two years. 
Treatment of the patient should include active exercise and functional 
activities.2,40 Sample exercises to correlate with Askari's functional 
classifications were given by Jennifer Grant,2 MS, PT. They have been reprinted 
in Table 2. Goals of treatment should be to increase strength, regain 
endurance, and teach energy conservation techniques. Assistive devices may 
be needed for some patients. Proper home instructions and referral to a 
physician should be made. 
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Table 2.-Sample Exercise Prescription Based on Functional Statusa 
Low Level Intermediate Level High Level Advanced Level 
Active range of Light resistive Toe raises in Bench step 
motion (AROM) exercise against standing position 
gravity 
Gravity eliminated Assisted bridging Bridging One-leg 
bridging 
Against gravity Semi-squats with Squats with Lunges 
upper extremity extremity support 
support 
Chair pushups Half kneel to 
standing position 
aReprinted with permission. Grant J. Corticosteroid side effects: implications 
for PT. PT Mag Phys Ther. 1994;2:56-60. 
CHAPTER VIII 
CONCLUSION 
This project discussed a few of the possible adverse effects of CS use 
and their implications for the physical therapist. A physical therapist cannot 
decide whether or not a patient should be on CS. However, he/she should be 
aware of the signs and symptoms of the possible adverse effects from the use of 
these medications which may be apparent during evaluation and/or assessment. 
Being aware of the medication complications will allow the therapist to 
make the appropriate clinical decision and provide quality care to that patient. 
The therapist may have to alter how he/she conducts the evaluation. When 
planning the treatment and progression of a patient, the therapist must also take 
into consideration the secondary effects of CS, whether it be osteoporosis, a 
compromised immune system, GI complications, avascular necrosis, 
neuropsychological difficulties, or steroid myopathy. 
It is also the duty of the physical therapist to inform the physician of any 
observed changes in the patient's functioning, such as a decrease in the 
proximal strength of the lower extremities and a decrease in general endurance. 
A therapist will know how to treat steroid myopathy, but the physician may also 
be able to decrease the dosage of CS or switch the patient to another form of 
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CS. The therapist and physician together can help the patient maintain his/her 
highest level of function. 
The adverse effects discussed mayor may not affect a patient receiving 
CS. Throughout the literature it seems apparent that the adverse effects are 
very patient specific. Patient susceptibility to CS may playa significant role in 
whether or not he/she will develop any of the adverse effects and to what extent 
they will affect the patient. 
Although CS are therapeutic agents, one question remains. Do the 
benefits of CS in treating the primary diagnosis outweigh the risks and 
consequences of the adverse effects? It is a Catch 22. On one hand, the 
primary diagnosis may be exacerbated without the use of corticosteroids, but on 
the other hand, the adverse effects of CS may be debilitating. But in most 
cases, the benefits of CS outweigh the potential adverse effects. 
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